Humoral and cellular immunity to plasmodium falciparum merozoite surface protein 1 and protection from infection with blood-stage parasites

Journal of Infectious Diseases

Volumn 208, Issue 1, 2013, Pages 149-158

  Moormann, Ann M ^a,c,d   Sumba, Peter Odada ^g   Chelimo, Kiprotich ^g,h   Fang, Hua ^d   Tisch, Daniel J ^a   Dent, Arlene E ^a,b   John, Chandy C ^e   Long, Carole A ^f   Vulule, John ^g   Kazura, James W ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c Department of Pediatrics ^*  (United States)

^d UNIVERSITY OF MASSACHUSETTS   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^g KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^h MASENO UNIVERSITY   (Kenya)

Author keywords

cellular immunity; human immunity; humoral immunity; interferon gamma; interleukin 10; longitudinal study; Merozoite Surface Protein 1; observational study; sickle cell trait

Indexed keywords

BIOLOGICAL MARKER; GAMMA INTERFERON; IMMUNOGLOBULIN G; INTERLEUKIN 10; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1;

ADAPTIVE IMMUNITY; ADOLESCENT; ADULT; AGE; AGED; ALLELE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CHILD; CONTROLLED STUDY; CYTOKINE RESPONSE; ENDEMIC DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; GENOTYPE; HUMAN; HUMORAL IMMUNITY; INFECTION RISK; KENYA; MALARIA CONTROL; MALARIA FALCIPARUM; PARASITEMIA; PLASMODIUM FALCIPARUM; PRESCHOOL CHILD; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; REINFECTION; RISK ASSESSMENT; SCHOOL CHILD; VACCINE PRODUCTION;

CELLULAR IMMUNITY; HUMAN IMMUNITY; HUMORAL IMMUNITY; INTERFERON-GAMMA; INTERLEUKIN-10; LONGITUDINAL STUDY; MEROZOITE SURFACE PROTEIN 1; OBSERVATIONAL STUDY; SICKLE CELL TRAIT;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HEMOGLOBIN, SICKLE; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOGLOBULIN G; INFANT; INTERFERON-GAMMA; INTERLEUKIN-10; KENYA; MALARIA, FALCIPARUM; MALE; MEROZOITE SURFACE PROTEIN 1; MIDDLE AGED; PARASITEMIA; PLASMODIUM FALCIPARUM; YOUNG ADULT;

EID: 84878556137     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit134     Document Type: Article

References (50)

1. Moonen B, Cohen JM, Snow RW, et al. Operational strategies to achieve and maintain malaria elimination. Lancet 2010; 376:1592-603.
2. Doolan DL, Dobano C, Baird JK. Acquired immunity to malaria. Clin Microbiol Rev 2009; 22:13-36, Table of Contents.
3. Fowkes FJ, Richards JS, Simpson JA, Beeson JG. The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: a systematic review and meta-analysis. PLoS Med 2010; 7:e1000218.
4. Cohen S, McGregor IA, Carrington S. Gamma-globulin and acquired immunity to human malaria. Nature 1961; 192:733-7.
5. Sabchareon A, Burnouf T, Ouattara D, et al. Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Am J Trop Med Hyg 1991; 45:297-308.
6. Greenhouse B, Slater M, Njama-Meya D, et al. Decreasing efficacy of antimalarial combination therapy in Uganda is explained by decreasing host immunity rather than increasing drug resistance. J Infect Dis 2009; 199:758-65.
7. John CC, Tande AJ, Moormann AM, et al. Antibodies to pre-erythrocytic Plasmodium falciparum antigens and risk of clinical malaria in Kenyan children. J Infect Dis 2008; 197:519-26.
8. Langhorne J, Ndungu FM, Sponaas AM, Marsh K. Immunity to malaria: more questions than answers. Nat Immunol 2008; 9:725-32.
9. Roestenberg M, McCall M, Hopman J, et al. Protection against a malaria challenge by sporozoite inoculation. N Engl J Med 2009; 361:468-77.
10. Pombo DJ, Lawrence G, Hirunpetcharat C, et al. Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet 2002; 360:610-7.
11. Bejon P, Mwacharo J, Kai O, et al. The induction and persistence of T cell IFN-gamma responses after vaccination or natural exposure is suppressed by Plasmodium falciparum. J Immunol 2007; 179:4193-201.
12. McCall MB, Sauerwein RW. Interferon-gamma-central mediator of protective immune responses against the pre-erythrocytic and blood stage of malaria. J Leukoc Biol 2010; 88:1131-43.
13. Struik SS, Riley EM. Does malaria suffer from lack of memory? Immunol Rev 2004; 201:268-90.
14. Genton B. Malaria vaccines: a toy for travelers or a tool for eradication? Expert Rev Vaccines 2008; 7:597-611.
15. Holder AA. The carboxy-terminus of merozoite surface protein 1: structure, specific antibodies and immunity to malaria. Parasitology 2009; 136:1445-56.
16. Ogutu BR, Apollo OJ, McKinney D, et al. Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. PLoS One 2009; 4: e4708.
17. Sheehy SH, Duncan CJ, Elias SC, et al. Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVAvaccine vectors. Mol Ther 2011; 19:2269-76.
18. de Cassan SC, Forbes EK, Douglas AD, et al. The requirement for potent adjuvants to enhance the immunogenicity and protective efficacy of protein vaccines can be overcome by prior immunization with a recombinant adenovirus. J Immunol 2011; 187:2602-16.
19. Qian F, Reiter K, Zhang Y, et al. Immunogenicity of self-associated aggregates and chemically cross-linked conjugates of the 42 kDa Plasmodium falciparum merozoite surface protein-1. PLoS One 2012; 7: e36996.
20. Singh S, Miura K, Zhou H, et al. Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity. Infect Immun 2006; 74: 4573-80.
21. Kawabata Y, Udono H, Honma K, et al. Merozoite surface protein 1-specific immune response is protective against exoerythrocytic forms of Plasmodium yoelii. Infect Immun 2002; 70:6075-82.
22. Wipasa J, Hirunpetcharat C, Mahakunkijcharoen Y, Xu H, Elliott S, Good MF. Identification of T cell epitopes on the 33-kDa fragment of Plasmodium yoelii merozoite surface protein 1 and their antibody-independent protective role in immunity to blood stage malaria. J Immunol 2002; 169:944-51.
23. KeitelWA, Kester KE, Atmar RL, et al. Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoid. Vaccine 1999; 18:531-9.
24. Pusic KM, Hashimoto CN, Lehrer A, Aniya C, Clements DE, Hui GS. T cell epitope regions of the P. falciparum MSP1-33 critically influence immune responses and in vitro efficacy of MSP1-42 vaccines. PLoS One 2011; 6:e24782.
25. Kiwanuka GN. Genetic diversity in Plasmodium falciparum merozoite surface protein 1 and 2 coding genes and its implications in malaria epidemiology: a review of published studies from 1997-2007. J Vector Borne Dis 2009; 46:1-12.
26. Thera MA, Doumbo OK, Coulibaly D, et al. A field trial to assess a blood-stage malaria vaccine. N Engl J Med 2011; 365:1004-13.
27. Qari SH, Shi YP, Goldman IF, Nahlen BL, Tibayrenc M, Lal AA. Predicted and observed alleles of Plasmodium falciparum merozoite surface protein-1 (MSP-1), a potential malaria vaccine antigen. Mol Biochem Parasitol 1998; 92:241-52.
28. Moormann AM, John CC, Sumba PO, Tisch D, Embury P, Kazura JW. Stability of interferon-gamma and interleukin-10 responses to Plasmodium falciparum liver stage antigen-1 and thrombospondin-related adhesive protein in residents of a malaria holoendemic area. Am J Trop Med Hyg 2006; 74:585-90.
29. Spring MD, Chelimo K, Tisch DJ, et al. Allele specificity of gamma interferon responses to the carboxyl-terminal region of Plasmodium falciparum merozoite surface protein 1 by Kenyan adults with naturally acquired immunity to malaria. Infect Immun 2010; 78:4431-41.
30. Husain SM, Kalavathi P, Anandaraj MP. Analysis of sickle cell gene using polymerase chain reaction & restriction enzyme Bsu 361. Indian J Med Res 1995; 101:273-6.
31. Bloland PB, Boriga DA, Ruebush TK, et al. Longitudinal cohort study of the epidemiology of malaria infections in an area of intense malaria transmission II. Descriptive epidemiology of malaria infection and disease among children. Am J Trop Med Hyg 1999; 60:641-8.
32. Freitas do Rosario AP, Langhorne J. T cell-derived IL-10 and its impact on the regulation of host responses during malaria. Int J Parasitol 2012; 42:549-55.
33. Dent AE, Moormann AM, Yohn CT, et al. Broadly reactive antibodies specific for Plasmodium falciparum MSP-119 are associated with the protection of naturally exposed children against infection. Malar J 2012; 11:287.
34. Crompton PD, Traore B, Kayentao K, et al. Sickle cell trait is associated with a delayed onset of malaria: implications for time-to-event analysis in clinical studies of malaria. J Infect Dis 2008; 198:1265-75.
35. Moormann AM. How might infant and paediatric immune responses influence malaria vaccine efficacy? Parasite Immunol 2009; 31:547-59.
36. Kinyanjui SM, Bejon P, Osier FH, Bull PC, Marsh K. What you see is not what you get: implications of the brevity of antibody responses to malaria antigens and transmission heterogeneity in longitudinal studies of malaria immunity. Malar J 2009; 8:242.
37. Crompton PD, Kayala MA, Traore B, et al. A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray. Proc Natl Acad Sci U S A 2010; 107: 6958-63.
38. Stanisic DI, Richards JS, McCallum FJ, et al. Immunoglobulin G subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness. Infect Immun 2009; 77:1165-74.
39. John CC, O'Donnell RA, Sumba PO, et al. Evidence that invasioninhibitory antibodies specific for the 19-kDa fragment of merozoite surface protein-1 (MSP-1 19) can play a protective role against bloodstage Plasmodium falciparum infection in individuals in a malaria endemic area of Africa. J Immunol 2004; 173:666-72.
40. Barry AE, Trieu A, Fowkes FJ, et al. The stability and complexity of antibody responses to the major surface antigen of Plasmodium falciparum are associated with age in a malaria endemic area. Mol Cell Proteomics 2011; 10:M111 008326.
41. Huaman MC, Martin LB, Malkin E, et al. Ex vivo cytokine and memory T cell responses to the 42-kDa fragment of Plasmodium falciparum merozoite surface protein-1 in vaccinated volunteers. J Immunol 2008; 180:1451-61.
42. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008; 8:247-58.
43. Chelimo K, Embury PB, Sumba PO, et al. Age-related differences in naturally acquired T cell memory to Plasmodium falciparum merozoite surface protein PLoS One 2011; 6:e24852.
44. Sun T, Holowka T, Song Y, et al. A Plasmodium-encoded cytokine suppresses T-cell immunity during malaria. Proc Natl Acad Sci U S A 2012; 109:E2117-26.
45. Riley EM, Morris-Jones S, Blackman MJ, Greenwood BM, Holder AA. A longitudinal study of naturally acquired cellular and humoral immune responses to a merozoite surface protein (MSP1) of Plasmodium falciparum in an area of seasonal malaria transmission. Parasite Immunol 1993; 15:513-24.
46. Kemp DJ. Antigenic diversity and variation in blood stages of Plasmodium falciparum. Immunol Cell Biol 1992; 70(Pt 3):201-7.
47. Pinkevych M, Petravic J, Chelimo K, Kazura JW, Moormann AM, Davenport MP. The dynamics of naturally acquired immunity to Plasmodium falciparum infection. PLoS Comput Biol 2012; 8:e1002729.
48. Dent AE, Chelimo K, Sumba PO, et al. Temporal stability of naturally acquired immunity to merozoite surface protein-1 in Kenyan adults. Malar J 2009; 8:162.
49. Hui G, Hashimoto C. Plasmodium falciparum anti-MSP1-19 antibodies induced by MSP1-42 and MSP1-19 based vaccines differed in specificity and parasite growth inhibition in terms of recognition of conserved versus variant epitopes. Vaccine 2007; 25:948-56.
50. Lyon JA, Angov E, Fay MP, et al. Protection induced by Plasmodium falciparum MSP1(42) is strain-specific, antigen and adjuvant dependent, and correlates with antibody responses. PLoS One 2008; 3:e2830.